Asset Details
Do you wish to reserve the book?
Meta-analysis of published efficacy and safety data for docetaxel in second-line treatment of patients with advanced non-small-cell lung cancer
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Meta-analysis of published efficacy and safety data for docetaxel in second-line treatment of patients with advanced non-small-cell lung cancer
Do you wish to request the book?
Meta-analysis of published efficacy and safety data for docetaxel in second-line treatment of patients with advanced non-small-cell lung cancer
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Meta-analysis of published efficacy and safety data for docetaxel in second-line treatment of patients with advanced non-small-cell lung cancer
2016
Overview
Purpose
To gain a better understanding of the impact of dose and other prognostic factors on safety and efficacy of docetaxel in second-line non-small-cell lung cancer patients.
Methods
A model-based meta‐analysis (MBMA) of a published docetaxel monotherapy data in 6085 second‐line non-small-cell lung cancer patients from 46 trials was conducted.
Results
The logit of grade 3/4 neutropenia incidence was a linear function of dose, with a 5 % increase in the odds of neutropenia per mg/m
2
increase in dose [odds ratio (OR) 1.05, 95 % confidence interval (CI) 1.04–1.06], and a Japanese study effect (OR 17.1, 95 % CI 6.05–48.4). The logit of overall response rate (ORR) was a linear function of cumulative dose (0.4 % increase in the odds of response per mg/m
2
increase; OR 1.004, 95 % CI 1.001–1.008) and median population age (OR 1.08 per year, 95 % CI 1.02–1.15). A Japanese study effect was identified for overall survival (OS) in addition to prognostic factors identified by a previous meta-analysis.
Conclusions
This current MBMA identified docetaxel dose–response relationships for both neutropenia and ORR, an effect of age on ORR, and Japanese study effects on both neutropenia and OS.
Publisher
Springer Berlin Heidelberg,Springer Nature B.V
Subject
Antineoplastic Agents - administration & dosage
/ Antineoplastic Agents - adverse effects
/ Antineoplastic Agents - therapeutic use
/ Carcinoma, Non-Small-Cell Lung - drug therapy
/ Carcinoma, Non-Small-Cell Lung - pathology
/ Dose-Response Relationship, Drug
/ Humans
/ Lung Neoplasms - drug therapy
/ Medicine
/ Neutropenia - chemically induced
/ Oncology
